Neurocritical Care
Role of nicotine replacement therapy (NRT) β Smoking is a common risk factor for developing cerebral
aneurysms.
Nicotine administration to naive users causes vasoconstriction, whereas administration to
heavy users causes little reaction. Nicotine withdrawal in heavy users causes acute, temporary
vasodilation, which may lead to headaches.
Seder et al.: Neurocrit Care 2011;14:77-83: Evaluated safety of NRT in active cigarette smokers
admitted with an aneurysmal SAH and included 128 who received NRT and 106 who did not.
Despite its vasoactive properties, NRT administered among active smokers with acute aneurysmal
SAH appeared safe, with similar rates of vasospasm and delayed cerebral ischemia and a slightly
higher rate of seizures.
disposition among neurosurgery ICU patients who were smokers treated with NRT (n=114), smokers
not treated with NRT (n=113), and nonsmokers not treated with NRT (n=113). Primary admitting
diagnosis for neurosurgery patients included SAH, ICH, other trauma, and elective neurosurgery.
Administration technique -- typically administered during cerebral angiography
infusionβ)
Calcium channel blockers
Typically used for cerebral vasospasm associated with SAH
Direct, local infusion typically results in immediate vasodilation.
Usually effective in proximal and distal vessels
verapamil vs. nicardipine plus verapamil plus nitroglycerin) for arterial lumen restoration post-cerebral
vasospasm after aneurysmal SAH (Intra-arterial Vasospasm Trial at https://clinicaltrials.gov/ct2/show/
record/NCT01996436).
Agent
Typical Dose
Adverse Effects
Nicardipine
2β25 mg, up to 5
mg/vessel
Systemic hypotension
Increased ICP
Verapamil
1β10 mg
Systemic hypotension
Bradycardia
Increased ICP
Milrinone
5β15 mg
Systemic hypotension
ICP = intracranial pressure.
Most often used in patients with ischemic stroke
Current roles